[1]李劲松.核素治疗转移性骨癌骨痛的展望[J].国际放射医学核医学杂志,2000,24(3):110-112.
　LI Jing-song.Expectation of radionuclide analgesic therapy in patients with metastatic carcinoma of bone[J].International Journal of Radiation Medicine and Nuclear Medicine,2000,24(3):110-112.
点击复制

核素治疗转移性骨癌骨痛的展望(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
24
期数:
2000年第3期
页码:
110-112
栏目:
综述
出版日期:
1900-01-01

文章信息/Info

Title:
Expectation of radionuclide analgesic therapy in patients with metastatic carcinoma of bone
作者:
李劲松
200092 上海, 上海第二医科大学附属新华医院核医学科
Author(s):
LI Jing-song
Department of Nuclear Medicine, Affiliated Xinhua Hospital, Shanghai Second Medical University, Shanghai 200092, China
关键词:
核素治疗; 骨转移癌; 骨痛
Keywords:
radionuclide therapy; matastatic carcinoma of bone; osteocopic pain
分类号:
R817. 5
摘要:
就目前临床上常用的几种治疗骨痛用核素药物的特点进行比较,并介绍一种被寄予厚望的、可由核素发生器生产的、188Re标记的药物188Re-HEDP,同时,就建立全国可行的核素治疗骨转移癌骨痛疗效的评定标准,提出了建议。
Abstract:
The characteristic of several common radioactive analgesics are compared. Also a greatly expected new drug, 188Re-HEDP is introduced for its superior radio-physical and radio-chemical property. At last, advice is given about the national-wide evaluating standard of radionuclide analgesic therapy of osteocopic pain.

参考文献/References:

[1] 曹京旭.靶性放射性核素治疗骨转移[J].国外医学·放射医学核医学分册, 1995, 19(4):153~156.
[2] Cameron PS, Klemp PF, Martindale AA, et al. Pro-spective 153Sm-EDTMP therapy dosimetry by whole body scintigraphy[J]. Nucl Med Commun, 1999, 20(7):609~615.
[3] Friedland J. Local and systemic radiation for palliation of metastatic disease[J]. Urol Clin North Am, 1999,26(2):391~402.
[4] 金稚奎. 骨转移瘤的放射性核素治疗[J].国外医学·放射医学核医学分册, 1995, 19(4):145~148.
[5] Quirijnen JM, Han SH, Zonnenberg BA, et al.Efficacy of rhenium-186-etidronate in prostate cancer patients with metastatic bone pine[J]. J Nucl Med,1996, 37(9):1511~1515.
[6] Limouris GS, Shukla SK, Condi PA, et al. Palliative therapy using rhenium-186-HEDP in painful breast osseous metastases[J]. Anticancer Res, 1997, 17(3B):1767~1779.
[7] Palmedo H, Bender H, Schomburg A, et al. Pain therapy with rhenium-186-HEDP in multiple bone metastases[J]. J Nucl Med, 1996, 35(2):63~67.
[8] de Klerk JMH, van het Schip AD, Zonnenherg BA, et al. Phase 1 study of rhenium-186-HEDP in patients with bone metastases originating from breast cancer[J]. J Nucl Med, 1996, 37(1):38~41.
[9] Lin WY, Lin CP,Yeh SJ, et al. Rhenium-188 hydroxyethylidene diphosphonate:a. new generator-produced radiotherapeutic drug of potential value for the treatment of bone metastases[J]. Eur J Nucl Med, 1997, 24(6):590~595.
[10] 林祥通.关于放射性核素治疗骨转移所致疼痛的疗效评价[J].中华核医学杂志, 1995, 15(2):123.

相似文献/References:

[1]罗全勇.基因转染诱导核素靶向治疗的实验研究[J].国际放射医学核医学杂志,2001,25(2):60.
　LUO Quan-yong.Inducement of radionuclides targeting therapy by gene transfection[J].International Journal of Radiation Medicine and Nuclear Medicine,2001,25(3):60.
[2]卓杰,周荫葆.153Sm－EDTMP的临床应用及其副作用[J].国际放射医学核医学杂志,1996,20(5):212.
[3]何晓娃,周荫保.153Sm-EDTMP治疗骨痛及其毒性[J].国际放射医学核医学杂志,1995,19(4):148.

备注/Memo

备注/Memo:
收稿日期:1999-03-09。
作者简介:李劲松(1965-),男,山东曹县人,上海第二医科大学附属新华医院核医学科主治医师,医学学士,主要从事肿瘤核素治疗研究。
更新日期/Last Update: 1900-01-01